Dr Reddy’s Sees Tocilizumab Clear Phase I
Indian Firm’s Biosimilar Rival To Actemra/RoActemra Moves Into Phase III Trials
Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.
You may also be interested in...
Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).
Bio-Thera Claims A World First With Chinese Tocilizumab Approval
Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.
Celltrion Gets Ready To Push Tocilizumab Into Phase III
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.